Novartis keeps a close eye on gene therapy with Vedere Bio buyAlready a major player in gene therapy, Novartis has swooped on US startup Vedere Bio in a $280 Share XNovartis keeps a close eye on gene therapy with Vedere Bio buyhttps://pharmaphorum.com/news/novartis-keeps-a-close-eye-on-gene-therapy-with-vedere-bio-buy/